Helping patients reclaim a life of possibility
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…
On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first…
At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the…
The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is…
Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland (NI). Myeloma Forward will hold bi-monthly meetings where speakers talk about some aspect of living with myeloma and share experiences and stories, providing peer support…
MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria. Plasma donations are needed from people to produce immunoglobulin replacement therapy (you might hear it called IVIG) which is used in myeloma to reduce the risk of infection. It is of interest to MPE because myeloma…
Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET. A generic medicine has the same active ingredient as a branded medicine and can be produced after the patent for the branded medicine expires. For…
The US Food and Drug Administration (FDA) has issued draft guidance to the pharmaceutical industry on using minimal residual disease (MRD) and complete response (CR) in myeloma clinical trials as a primary endpoint, to support approval under accelerated assessment. This follows a previous decision of the US FDA’s Oncology Drugs Advisory Committee (ODAC) to accept…